Opus Genetics 관리

관리 기준 확인 2/4

Opus Genetics CEO는 George Magrath, Nov2023 에 임명되었습니다 의 임기는 1.5 년입니다. 총 연간 보상은 $ 889.24K, 64.7% 로 구성됩니다. 64.7% 급여 및 35.3% 보너스(회사 주식 및 옵션 포함). 는 € 578.38K 가치에 해당하는 회사 주식의 1.52% 직접 소유합니다. 578.38K. 경영진과 이사회의 평균 재임 기간은 각각 1.4 년과 4.5 년입니다.

주요 정보

George Magrath

최고 경영자

US$889.2k

총 보상

CEO 급여 비율	64.7%
CEO 임기	1.5yrs
CEO 소유권	1.5%
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	4.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

George Magrath 의 보수는 Opus Genetics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2024	US$889k	US$575k	-US$58m
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$3m	US$96k	-US$10m

보상 대 시장: George 의 총 보상 ($USD 889.24K )은 German 시장( $USD 497.04K ).

보상과 수익: George 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

George Magrath (40 yo)

1.5yrs

테뉴어

US$889,238

보상

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited si...

리더십 팀

이름	위치	테뉴어	보상	소유권
George Magrath	CEO & Director	1.5yrs	US$889.24k	1.52% € 578.4k
Benjamin Yerxa	President & Director	less than a year	데이터 없음	0.022% € 8.4k
Nirav Suresh Jhaveri	Chief Financial Officer	1.3yrs	US$1.39m	0.081% € 30.8k
Ashwath Jayagopal	Chief Scientific & Development Officer	1.3yrs	US$1.24m	0.037% € 14.3k
Joseph Schachle	Chief Operating Officer	1.5yrs	데이터 없음	0.0044% € 1.7k
Bernhard Hoffmann	Senior Vice President of Corporate Development & Secretary	no data	US$789.92k	0.26% € 98.4k
Amy Zaremba Rabourn	Senior Vice President of Finance	no data	US$789.92k	0.047% € 17.7k
Bindu Manne	Head of Market Development & Commercialization	3.3yrs	데이터 없음	데이터 없음
Erik Sims	Director & Corporate Controller	no data	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: R3X1 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
George Magrath	CEO & Director	1.5yrs	US$889.24k	1.52% € 578.4k
Benjamin Yerxa	President & Director	no data	데이터 없음	0.022% € 8.4k
James S. Manuso	Independent Director	4.5yrs	US$184.43k	0.31% € 118.1k
Adrienne Graves	Independent Director	less than a year	US$192.82k	데이터 없음
David Boyer	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Richard Rodgers	Independent Director	4.5yrs	US$267.48k	0.53% € 200.1k
Susan Benton	Independent Director	4.5yrs	US$176.39k	0.31% € 117.1k
Cameron Gallagher	Independent Chairman	4.5yrs	US$219.61k	1.89% € 720.6k
Sean Ainsworth	Lead Independent Director	4.5yrs	US$200.22k	0.10% € 39.5k
Jean Bennett	Director	less than a year	US$325.82k	0.075% € 28.5k
Arshad Khanani	Member of Medical Advisory Board	1.2yrs	데이터 없음	데이터 없음
Mark Pennesi	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: R3X1 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/06 17:29
장 마감 주가	2025/05/05 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Opus Genetics, Inc. 4 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
James Molloy	Alliance Global Partners
Gum-Ming Lowe	Craig-Hallum Capital Group LLC
Matthew Caufield	H.C. Wainwright & Co.

Opus Genetics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Recent updates

Opus Genetics Announces One-Year Results from Adult Patients Treated in the Ongoing Phase 1/2 Study of Its Lead Gene Therapy Candidate OPGx-LCA5

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

Opus Genetics, Inc., Annual General Meeting, Apr 30, 2025

Opus Genetics, Inc. announced that it has received $1.500001 million in funding

Opus Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Opus Genetics, Inc. Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025

Opus Genetics, Inc. Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics, Inc. Announces First Pediatric Patient Was Dosed in its Ongoing Phase 1/2 Clinical Trial Evaluating OPGx-LCA5, its Investigational Gene Therapy for the Treatment of Leber Congenital Amaurosis

Opus Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million.

Opus Genetics, Inc. to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

Third quarter 2024 earnings released: US$0.29 loss per share (vs US$0.26 profit in 3Q 2023)

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.28 loss in 1Q 2023)

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

New minor risk - Profitability

Full year 2023 earnings released: US$0.46 loss per share (vs US$0.90 profit in FY 2022)

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 15%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 15%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Investor sentiment improves as stock rises 16%

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 24%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Ocuphire Pharma, Inc. Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis

Forecast to breakeven in 2022

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol and Strategic Partnership with American Society of Ophthalmic Administrators

Ocuphire Expands Medical Advisory Board with Seven New Kols and Strengthens Leadership Team

Ocuphire Pharma, Inc. Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics At Annual Macula Society Meeting

Ocuphire Pharma, Inc., Annual General Meeting, Jun 13, 2022

Ocuphire Pharma, Inc. Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Forecast to breakeven in 2024

High number of new directors

No longer forecast to breakeven

Ocuphire Pharma, Inc. Appoints Jay Pepose as Chief Medical Advisor

Ocuphire Pharma, Inc. Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations

Ocuphire Pharma, Inc. Provides Update on its APX3330 and Nyxol Clinical Programs

Ocuphire Pharma, Inc. Initiates Enrollment of Nyxol Mira-4 Pediatric Study in Rm Per Agreed Initial Pediatric Study Plan with FDA

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis

Board Member recently bought €51k worth of stock

Insider recently bought €77k worth of stock

Ocuphire Pharma, Inc. Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease